Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bristol Myers Squibb : U.S. Patents Awarded to Inventors in Connecticut (Nov. 10)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 08:38pm CET

ALEXANDRIA, Va., Nov. 10 -- The following federal patents were awarded to inventors in Connecticut.

***

Temptime Assigned Patent for Computing Systems

ALEXANDRIA, Va., Nov. 10 -- Temptime, Morris Plains, New Jersey, has been assigned a patent (9,811,632) developed by six co-inventors for "computing systems and methods for electronically indicating the acceptability of a product." The co-inventors are Frederick Robert Grabiner, Livingston, New Jersey, Carl Michael Lentz, Cedar Knolls, New Jersey, Emily Moore, Haddam, Connecticut, Thaddeus Prusik, Stroudsburg, Pennsylvania, Nicholas Puro, Briarcliff Manor, New York, and Bruce-Erik Osborn, West Vancouver, Canada. The abstract states: "In part, the invention relates to computing systems and methods for electronically indicating the acceptability of a product. An image capture and communication device may analyze a product label that includes one or more monitors, authentication elements, and identification elements. The image capture and communication device may determine the type and features of the monitors, authentication elements, and identification elements. The image capture and communication device may transmit data based on the type and features to a host server, which may transmit data associated with the host product to the image capture and communication device in, inter alia, the form of an acceptability report."

The patent application was filed on Dec. 28, 2015 (14/981,457). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,811,632.PN.&OS=PN/9,811,632&RS=PN/9,811,632

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Immunomodulators

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,625) developed by two co-inventors for immunomodulators. The co-inventors are Kenneth M. Boy, Durham, Connecticut, and Paul Michael Scola, Glastonbury, Connecticut. The abstract states: "The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases."

The patent application was filed on March 14, 2016 (15/068,993). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,625.PN.&OS=PN/9,809,625&RS=PN/9,809,625

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

Bristol-Myers Squibb Assigned Patent for Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors

ALEXANDRIA, Va., Nov. 10 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (9,809,573) developed by six co-inventors for "substituted pyridine derivatives useful as GSK-3 inhibitors." The co-inventors are Guanglin Luo, Madison, Connecticut, Ling Chen, Middletown, Connecticut, Gene M. Dubowchik, Middlefield, Connecticut, Swanee E. Jacutin-Porte, Madison, Connecticut, Prasanna Sivaprakasam, Middletown, Connecticut, and John E. Macor, Washington Crossing, Pennsylvania. The abstract states: "The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system."

The patent application was filed on Nov. 3, 2014 (15/033,770). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,809,573.PN.&OS=PN/9,809,573&RS=PN/9,809,573

Written by Amal Ahmed; edited by Sudarshan Harpal.

***

P.F. Laboratories, Purdue Pharma, Purdue Pharmaceuticals Assigned Patent for Pharmaceutical Formulation Containing Opioid Agonist

ALEXANDRIA, Va., Nov. 10 -- P.F. Laboratories, Totowa, New Jersey, Purdue Pharma, Stamford, Connecticut, and Purdue Pharmaceuticals, Wilson, North Carolina, have been assigned a patent (9,808,453) developed by three co-inventors for "pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent." The co-inventors are Benjamin Oshlack, Boca Raton, Florida, Curtis Wright, Rockport, Massachusetts, and Christopher Breder, Greenwich, Connecticut. The abstract states: "Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid."

The patent application was filed on Dec. 19, 2016 (15/384,229). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,808,453.PN.&OS=PN/9,808,453&RS=PN/9,808,453

Written by Amal Ahmed; edited by Sudarshan Harpal.

TARGETED NEWS SERVICE: Myron Struck, editor; 703/304-1897; [email protected]; http://www.targetednews.com

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
08:44p First Data for NKTR-214 in Combination with OPDIVO® nivolumab for Patients wi..
11/20 Innate Pharma SA - Third quarter 2017 report
11/17 LABORATORY OF AMERICA : LabCorp Announces New Expanded Use for PD-L1 Test with B..
11/16 BRISTOL MYERS SQUIBB : Opdivo Plus Yervoy Combination Delivered Overall Survival..
11/16 BRISTOL MYERS SQUIBB : Trademark Application for "ACCESS VIROLOGY" Filed
11/16 BRISTOL MYERS SQUIBB : Opdivo nivolumab Demonstrates Superior Three-Year Surviva..
11/16 BRISTOL MYERS SQUIBB : to Highlight Clinical and Translational Research at the S..
11/16 BRISTOL MYERS SQUIBB : An Application for the Trademark "AVGLAZI" Has Been Filed..
11/16 BRISTOL MYERS SQUIBB : to Take Part in Jefferies London Healthcare Conference
11/16 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Yield New Information a..
More news
News from SeekingAlpha
08:33a YOUR DAILY PHARMA SCOOP : Roche Rallies, Alnylam Granted BTD, Celsion Soars
11/20 Roche Rocks On With More Good News
11/20 Pfizer Scores Sutent Win, But Bristol-Myers Looks To Steal Its Thunder
11/17 EXELIXIS : Primed For Excellence
11/17 DIVIDEND CHALLENGERS (AND NEAR-CHALL : 58 Increases Expected By The End Of Janua..
Financials ($)
Sales 2017 20 634 M
EBIT 2017 5 598 M
Net income 2017 4 351 M
Debt 2017 295 M
Yield 2017 2,60%
P/E ratio 2017 23,35
P/E ratio 2018 20,37
EV / Sales 2017 4,84x
EV / Sales 2018 4,61x
Capitalization 99 511 M
Chart BRISTOL-MYERS SQUIBB COMPA
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 63,1 $
Spread / Average Target 3,8%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY4.93%99 511
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550